Fulgent Genetics SEC Filings

Fulgent Genetics (FLGT) insider sale notice under Form 144/A: An individual affiliated with Fulgent Genetics reported a proposed sale of 696 shares of common stock through Morgan Stanley Smith Barney on 08/25/2025, valued at approximately $14,965.08. The shares were acquired on 02/23/2023 upon vesting of restricted stock awarded as equity compensation.

The filer also reported three prior sales in the past three months totaling 3,008 shares with gross proceeds of $61,398.47. Outstanding common shares are listed as 30,609,044, making these transactions immaterial to total share count. The filing is a routine Rule 144 compliance notice and includes the customary representation that no undisclosed material adverse information is known.

Form 144 filed for Fulgent Genetics, Inc. (FLGT) reporting a proposed sale of 1,199 shares of common stock through Morgan Stanley Smith Barney on 08/27/2025 on NASDAQ with an aggregate market value of $25,760.20. The filing shows the shares to be sold were acquired as restricted stock that vested on 02/26/2024 as equity compensation, with 25,350 shares originally issued to the holder on that date. The issuer has 30,609,044 shares outstanding per the notice. The filer disclosed multiple prior open-market sales by the same person in the past three months totaling 3,704 shares with gross proceeds reported on specific dates. The signer certifies no undisclosed material information and acknowledges Rule 144/10b5-1 representations.

Fulgent Genetics insider sale notice: This Form 144 reports that Hanlin Gao plans to sell 943 shares of Fulgent Genetics common stock through Morgan Stanley Smith Barney (New York) with an aggregate market value of $20,260.11 and an approximate sale date of 08/27/2025. The filing shows 30,609,044 shares outstanding for the issuer. The shares to be sold were acquired on 02/26/2024 as restricted stock that vested (21,146 shares acquired as equity compensation). The notice lists four prior sales by Hanlin Gao between 05/27/2025 and 08/25/2025, totaling 2,341 shares with gross proceeds reported for each transaction. The filer certifies no undisclosed material adverse information.

Xie Jian, President and COO of Fulgent Genetics (FLGT) reported a sale of 696 shares on 08/25/2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/23/2023. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, with a reported weighted-average price of $21.5016. After the sale, the reporting person beneficially owns 366,448 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust, of which he serves on the investment committee and for which he disclaims beneficial interest except for any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 08/26/2025.

Ming Hsieh, Fulgent Genetics (FLGT) director, CEO and 10% owner, reported a withholding of 2,115 common shares on 08/23/2025 at a price of $21.77 per share to satisfy tax withholding upon vesting of restricted stock units granted on 02/23/2023. After the withholding, Mr. Hsieh directly holds 807,225 shares and retains substantial indirect holdings: 7,895,115 shares held by a Dynasty Trust, 220,816 shares held by the Ming Hsieh Trust, and two 1,000-share UTMA accounts for which he is custodian. The Form 4 was signed by an attorney-in-fact on 08/26/2025. The filing clarifies the trust relationships and voting/dispositive powers for the indirect holdings.

Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc. (FLGT) reported a routine disposition on 08/23/2025 in which 670 shares of common stock were disposed (transaction code F) at a price of $21.77 per share. The filing explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023. After the withholding, the reporting person beneficially owned 339,158 shares directly. The Form 4 is signed by Paul Kim on 08/26/2025.

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock on 08/25/2025 to satisfy tax withholding from vested restricted stock units originally granted on February 23, 2023. The Form 4 shows 548 shares sold at a weighted-average price of $21.5016 (individual sale prices ranged from $21.46 to $21.57). After the sale, the reporting person beneficially owned 959,091 shares. The filing was submitted by attorney-in-fact Paul Kim on 08/26/2025.

Form 144 notice for Fulgent Genetics, Inc. (FLGT): An individual identified as Jian Xie proposes to sell 696 shares of the issuer's common stock through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $14,965.08 and an approximate sale date of 08/25/2025 on NASDAQ. The shares were acquired on 02/23/2023 as restricted stock vesting from Fulgent Genetics as equity compensation; the filer shows total acquired amount of 14,573 shares. The issuer has 30,609,044 shares outstanding. The filer reported three prior sales in the past three months totaling 3,008 shares for gross proceeds of $61,471.47. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.

Fulgent Genetics (FLGT) Q2-25 10-Q highlights

• Revenue: $81.8 m, up 15% YoY; 1H-25 revenue $155.3 m (+15%). Precision Diagnostics remains the largest line ($47.3 m, 58%).
• Gross margin: 42.1% vs 37.3% prior-year as cost discipline in laboratory services offsets mix shift.
• Operating loss: –$19.7 m (vs –$18.9 m). Operating expenses rose 19% to $54.1 m on higher G&A (+24%) and marketing spend (+43%).
• Net loss attributable to shareholders: –$19.0 m (EPS –$0.62) vs –$8.7 m (–$0.29). 1H-25 EPS –$0.99.
• Impairment: $9.9 m write-down of Helio Genomics investment drove other expense; without it, other income was $8.1 m interest.
• Cash & investments: $777 m (cash + marketable securities) with $87.9 m cash vs $55.1 m YE-24. Long-term securities declined $86 m as durations shortened; total assets $1.2 bn.
• Operating cash flow: –$34.6 m vs +$11.6 m prior year, due mainly to $33 m federal tax payments and higher receivables.
• Share activity: Repurchased $13.9 m stock YTD; share count 30.6 m.
• Customer concentration: One institutional customer accounted for 22% of Q2 revenue and 29% of receivables.
• Regulatory matters: DOJ CIDs on lab billing and HRSA audit remain open; SEC investigation closed with no action (previous $1 m accrual reversed).

Outlook: Management did not provide forward guidance in the filing. Revenue growth persists but profitability deteriorated due to higher opex and one-time impairment; cash position remains strong.